BOPW
MDGL icon

Brandywine Oak Private Wealth’s Madrigal Pharmaceuticals MDGL Stock Holding History

Brandywine Oak Private Wealth’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7
Closed – – 457
2018
Q4 		$0 Buy
+7
New +$1.08K ﹤0.01% 720

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brandywine Oak Private Wealth's MDGL Position: Q1 2019 in Review

Brandywine Oak Private Wealth sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2019, closing a stake of 7 shares.

Brandywine Oak Private Wealth first reported a position in MDGL in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 135 funds tracked by Wall St. Rank hold MDGL as of Q1 2019.

  • Brandywine Oak Private Wealth reported no remaining Madrigal Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Brandywine Oak Private Wealth sold 7 Madrigal Pharmaceuticals shares in Q1 2019.
  • Brandywine Oak Private Wealth first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Brandywine Oak Private Wealth's Madrigal Pharmaceuticals position peaked at $0 in Q4 2018.
  • 135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2019.

Based on Brandywine Oak Private Wealth's 13F filing for Q1 2019, filed 9 May 2019.